Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

The visual cues that drive the self-assessment of body size: Dissociation between fixation patterns and the key areas of the body for accurate judgement.

Irvine KR, McCarty K, Pollet TV, Cornelissen KK, Tovée MJ, Cornelissen PL.

Body Image. 2019 Jun;29:31-46. doi: 10.1016/j.bodyim.2019.02.006. Epub 2019 Mar 8.

PMID:
30852440
2.

Distorted body image influences body schema in individuals with negative bodily attitudes.

Irvine KR, McCarty K, McKenzie KJ, Pollet TV, Cornelissen KK, Tovée MJ, Cornelissen PL.

Neuropsychologia. 2019 Jan;122:38-50. doi: 10.1016/j.neuropsychologia.2018.11.015. Epub 2018 Nov 27.

PMID:
30500663
3.

GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1.

Rausch MP, Irvine KR, Antony PA, Restifo NP, Cresswell P, Hastings KT.

J Immunol. 2010 Sep 1;185(5):2828-35. doi: 10.4049/jimmunol.1000945. Epub 2010 Jul 28.

4.

Sympathetic nervous system control of anti-influenza CD8+ T cell responses.

Grebe KM, Hickman HD, Irvine KR, Takeda K, Bennink JR, Yewdell JW.

Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5300-5. doi: 10.1073/pnas.0808851106. Epub 2009 Mar 13.

5.

Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.

Shinoda K, Wyatt LS, Irvine KR, Moss B.

Virol J. 2009 Mar 3;6:28. doi: 10.1186/1743-422X-6-28.

6.

Terminal deoxynucleotidyl transferase establishes and broadens antiviral CD8+ T cell immunodominance hierarchies.

Haeryfar SM, Hickman HD, Irvine KR, Tscharke DC, Bennink JR, Yewdell JW.

J Immunol. 2008 Jul 1;181(1):649-59.

7.

Tumor-specific Th17-polarized cells eradicate large established melanoma.

Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan CC, Restifo NP.

Blood. 2008 Jul 15;112(2):362-73. doi: 10.1182/blood-2007-11-120998. Epub 2008 Mar 19.

8.

De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.

Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y, Zeng G, Wunderlich JR, Nguyen DM, Restifo NP, Schrump DS.

Cancer Res. 2006 Jan 15;66(2):1105-13.

9.

Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines.

Tscharke DC, Karupiah G, Zhou J, Palmore T, Irvine KR, Haeryfar SM, Williams S, Sidney J, Sette A, Bennink JR, Yewdell JW.

J Exp Med. 2005 Jan 3;201(1):95-104. Epub 2004 Dec 28.

10.

Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model.

Kaufman HL, Rao JB, Irvine KR, Bronte V, Rosenberg SA, Restifo NP.

J Immunother. 1999 Nov;22(6):489-96. Erratum in: J Immunother 2000 Jul-Aug;23(4):509. Irivine KR [corrected to Irvine KR].

11.

Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases.

Gnant MF, Noll LA, Irvine KR, Puhlmann M, Terrill RE, Alexander HR Jr, Bartlett DL.

J Natl Cancer Inst. 1999 Oct 20;91(20):1744-50.

PMID:
10528025
12.

Cancer therapy using a self-replicating RNA vaccine.

Ying H, Zaks TZ, Wang RF, Irvine KR, Kammula US, Marincola FM, Leitner WW, Restifo NP.

Nat Med. 1999 Jul;5(7):823-7.

13.

Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens.

Irvine KR, Parkhurst MR, Shulman EP, Tupesis JP, Custer M, Touloukian CE, Robbins PF, Yafal AG, Greenhalgh P, Sutmuller RP, Offringa R, Rosenberg SA, Restifo NP.

Cancer Res. 1999 Jun 1;59(11):2536-40.

14.

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP.

Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2982-7.

15.

CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge.

Gurunathan S, Irvine KR, Wu CY, Cohen JI, Thomas E, Prussin C, Restifo NP, Seder RA.

J Immunol. 1998 Nov 1;161(9):4563-71.

16.

Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization.

Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN.

J Exp Med. 1998 Sep 21;188(6):1075-82.

17.

Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization.

Surman DR, Irvine KR, Shulman EP, Allweis TM, Rosenberg SA, Restifo NP.

J Immunol Methods. 1998 May 1;214(1-2):51-62.

18.

gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.

Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP.

J Exp Med. 1998 Jul 20;188(2):277-86.

19.

Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors.

Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP.

J Natl Cancer Inst. 1997 Nov 5;89(21):1595-601.

PMID:
9362157
20.

Route of immunization and the therapeutic impact of recombinant anticancer vaccines.

Irvine KR, Chamberlain RS, Shulman EP, Rosenberg SA, Restifo NP.

J Natl Cancer Inst. 1997 Mar 5;89(5):390-2. Review. No abstract available.

PMID:
9060962
21.

IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.

Rao JB, Chamberlain RS, Bronte V, Carroll MW, Irvine KR, Moss B, Rosenberg SA, Restifo NP.

J Immunol. 1996 May 1;156(9):3357-65.

22.

Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.

Irvine KR, Rao JB, Rosenberg SA, Restifo NP.

J Immunol. 1996 Jan 1;156(1):238-45.

23.

The next wave of recombinant and synthetic anticancer vaccines.

Irvine KR, Restifo NP.

Semin Cancer Biol. 1995 Dec;6(6):337-47. Review.

24.

Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL.

Irvine KR, McCabe BJ, Rosenberg SA, Restifo NP.

J Immunol. 1995 May 1;154(9):4651-7.

25.

Antigen processing in vivo and the elicitation of primary CTL responses.

Restifo NP, Bacík I, Irvine KR, Yewdell JW, McCabe BJ, Anderson RW, Eisenlohr LC, Rosenberg SA, Bennink JR.

J Immunol. 1995 May 1;154(9):4414-22.

26.

Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.

McCabe BJ, Irvine KR, Nishimura MI, Yang JC, Spiess PJ, Shulman EP, Rosenberg SA, Restifo NP.

Cancer Res. 1995 Apr 15;55(8):1741-7.

27.

Enhancing the recognition of tumour associated antigens.

Restifo NP, Minev BR, Taggarse AS, McFarland BJ, Wang M, Irvine KR.

Folia Biol (Praha). 1994;40(1-2):74-88. Review.

Supplemental Content

Loading ...
Support Center